NCT05142527View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

April 30, 2024

Conditions
COVID-19
Interventions
DRUG

ADM03820

ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

OTHER

Placebo

Placebo

Sponsors
All Listed Sponsors
collaborator

Enabling Biotechnologies (EB)

UNKNOWN

lead

Alachua Government Services, Inc.

INDUSTRY